Correspondence 0001493152-23-008531 from Tharimmune, Inc. (THAR) (CIK 0001861657) (THAR)

Tharimmune, Inc. (THAR) (CIK 0001861657)
Date: March 22, 2023 · CIK: 0001861657 · Accession: 0001493152-23-008531

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-270684

Date

March 22, 2023

Author

Randy Milby

Form

CORRESP

Company

Tharimmune, Inc. (THAR) (CIK 0001861657)

Letter

Hillstream BioPharma, Inc.

Route 22 East, Suite 2000

Bridgewater, NJ 08807

March 22, 2023

VIA EDGAR

United States Securities and Exchange Commission

F Street, N.E.

Washington, D.C. 20549

Attention: Arzhang Navai

Re: Hillstream BioPharma, Inc.

Registration Statement on Form S-3

File No. 333-270684

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Hillstream BioPharma, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4:30 p.m., Eastern Standard Time, on Friday, March 24, 2023, or as soon thereafter as possible.

Please notify Nazia Khan of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (202) 747-2651 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request.

HILLSTREAM BIOPHARMA, INC.

By: /s/ Randy Milby

Name: Randy Milby

Title: Chief Executive Officer

-1-

Show Raw Text

CORRESP
1
filename1.htm

Hillstream
BioPharma, Inc.

1200
Route 22 East, Suite 2000

Bridgewater,
NJ 08807

March
22, 2023

VIA
EDGAR

United
States Securities and Exchange Commission

100
F Street, N.E.

Washington,
D.C. 20549

Attention:
Arzhang Navai

    Re:
    Hillstream
    BioPharma, Inc.

    Registration
    Statement on Form S-3

    File
    No. 333-270684

Ladies
and Gentlemen:

Pursuant
to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Hillstream BioPharma, Inc. (the “Company”)
respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective
at 4:30 p.m., Eastern Standard Time, on Friday, March 24, 2023, or as soon thereafter as possible.

Please
notify Nazia Khan of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (202) 747-2651 as soon as possible as to
the time the Registration Statement has been declared effective pursuant to this acceleration request.

    HILLSTREAM
    BIOPHARMA, INC.

    By:
    /s/
    Randy Milby

    Name:
    Randy
    Milby

    Title:
    Chief
    Executive Officer

      -1-

SecProbe.io